Combination of immune checkpoint inhibitors with chemoradiation is now standard of care for patients with locally advanced cervical cancer (LACC). Here, the authors report the results of a phase I trial of neoadjuvant vs concurrent atezolizumab (anti-PD-L1) with chemoradiation for LACC.
- Jyoti Mayadev
- Dmitriy Zamarin
- Russell J. Schilder
